FIL Ltd lowered its stake in shares of STERIS plc (NYSE:STE - Free Report) by 16.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 302,067 shares of the medical equipment provider's stock after selling 58,092 shares during the period. FIL Ltd owned approximately 0.31% of STERIS worth $62,093,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently modified their holdings of the stock. Franklin Resources Inc. boosted its stake in shares of STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider's stock worth $191,370,000 after buying an additional 529,308 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of STERIS by 30.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,970 shares of the medical equipment provider's stock worth $2,275,000 after purchasing an additional 2,583 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of STERIS during the 3rd quarter worth approximately $9,949,000. Merit Financial Group LLC acquired a new stake in shares of STERIS in the 4th quarter valued at approximately $260,000. Finally, Blue Trust Inc. boosted its holdings in shares of STERIS by 19.9% in the 4th quarter. Blue Trust Inc. now owns 1,128 shares of the medical equipment provider's stock valued at $232,000 after buying an additional 187 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a report on Thursday, April 10th. Stephens reiterated an "overweight" rating and set a $240.00 target price on shares of STERIS in a research note on Thursday, February 6th. Needham & Company LLC restated a "hold" rating on shares of STERIS in a research note on Monday, April 7th. Finally, Piper Sandler lifted their price objective on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $258.75.
Check Out Our Latest Stock Report on STERIS
STERIS Trading Down 1.2 %
STE traded down $2.78 during trading on Tuesday, hitting $221.23. The company's stock had a trading volume of 74,200 shares, compared to its average volume of 551,730. The firm has a market capitalization of $21.74 billion, a P/E ratio of 46.97 and a beta of 0.87. STERIS plc has a twelve month low of $197.82 and a twelve month high of $248.24. The stock's fifty day moving average price is $222.67 and its 200-day moving average price is $219.40. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32.
STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Analysts anticipate that STERIS plc will post 9.08 EPS for the current year.
STERIS Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 21st. Shareholders of record on Thursday, February 20th were issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 1.03%. The ex-dividend date was Thursday, February 20th. STERIS's dividend payout ratio (DPR) is 48.41%.
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
